Sanofi Steps Up Avapro Support While Bristol Awaits Vanlev And DuPont
Sanofi-Synthelabo is increasing its role in the co-promotion of Avapro ahead of Bristol-Myers Squibb's resubmission of the NDA for Vanlev.
You may also be interested in...
Organon's anti-thrombotic agent Arixtra could receive approval from FDA in mid-August, Organon President Hans Vemer told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011